Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
The Parliamentary Under-Secretary of State for Health and Social Care (Dr Caroline Johnson)
It is a pleasure to serve under your chairmanship, Sir Roger. I thank my hon. Friend the Member for Carshalton and Wallington (Elliot Colburn) for his kind words regarding the covid vaccine programme, and for bringing this important and timely debate to the House. It is timely because we started the covid-19 boosters autumn scheme just a few weeks ago.
Before I respond to the points that have been made in the debate and try to answer all the questions posed by right hon. and hon. Members, I thank Members—particularly those on the Opposition Benches, including the hon. Members for Denton and Reddish (Andrew Gwynne) and for Coatbridge, Chryston and Bellshill (Steven Bonnar)—for their support for the vaccine scheme. I also thank each and every person in the country who has come forward for their jabs, as well as the tens of thousands of NHS staff and volunteers who made that happen.
My hon. Friend the Member for Carshalton and Wallington asked why the vaccine programme had worked so well. It worked so well because of the dedication and hard work of all who were involved in it—from the Government to the NHS, and from the volunteers to pharma. I was honoured to volunteer alongside people from my local area as young as 15 and as old as in their 80s. It was truly a community effort.
The take-up of the covid-19 vaccine has been huge, and over 151 million vaccines have been delivered in the UK, meaning that more than 90% of people aged 12 and over have received at least one dose and more than 40 million have received a booster or third dose. We have also made a great start to the autumn booster campaign. Since the start of the campaign on 5 September, more than 10 million people in England have stepped forward for their jabs.
Our safe and effective vaccines have underpinned the Government’s strategy for living with covid-19. They have allowed the economy and society to reopen, and the country’s ability to live with the virus in the future will continue to depend on deeper and broader population immunity. Critically, they have also reduced the pressure on the national health service and allowed us to start to tackle the elective care backlog.
Vaccines remain our biggest line of defence as we head into a challenging winter period. Vaccinated people are less likely to get seriously ill with covid-19 or seasonal flu, or to be admitted to hospital, and there is also evidence that they are less likely to pass the virus on to others. We know the covid vaccine has saved tens of thousands of lives—that is tens of thousands of mothers, fathers, husbands, wives, sisters, brothers, sons and daughters who are thankfully still with us.
Andrew Bridgen
Is the Minister aware that excess deaths run somewhere—there are two different sets of figures—between 18,000 and 25,000 this year alone?
Dr Johnson
I am referring to the covid vaccine, which has saved hundreds of thousands of lives. I take my hon. Friend’s point, but there is no evidence that those deaths were caused by the covid vaccine. Let me acknowledge and pass on my sympathies to the very small number of people for whom vaccines may not have worked as intended, and who may have suffered an adverse reaction from vaccines.
I turn to vaccine safety. All vaccines used in the UK covid-19 vaccine programme are safe. In the UK we have some of the highest safety standards in the world. The MHRA is globally recognised for high standards of quality, safety and medicines regulation. Each covid-19 vaccine candidate is assessed by teams of scientists and clinicians on a case-by-case basis. There are extensive checks and balances at every stage of vaccine development. It is only once each potential vaccine has met robust standards of effectiveness, safety and quality set by the MHRA that it will be approved for use.
It is also important to stress that the surveillance of vaccine safety and adverse reactions does not stop once a vaccine has been approved. The MHRA and the UK Health Security Agency constantly review a wide range of available data on the safety of vaccines, including UK and international reports of adverse reactions.
Sir John Hayes
People outside the House will not know that although the Minister has been in her job a relatively short time, she is a remarkably dedicated and diligent person. No Minister is more likely or determined than she is to get to the facts when looking at the international data. Will the Minister give the assurance that she will consider all the information available, including that international data, when she draws conclusions about the content of this debate and the cases that have been made by many of my constituents and others?
Dr Johnson
I thank my right hon. Friend for his kind words. I will, of course, look at all the evidence. He is aware of my experience as a clinician and he knows that I will look at the evidence-based medical process.
As part of the surveillance into currently used medicines and vaccines, the MHRA continues to review all the suspected adverse drug reaction reports—known as the yellow card reports—relating to covid vaccines, which right hon. and hon. Members have mentioned. Through the MHRA yellow card scheme, members of the public and healthcare professionals can report any suspected side effects. A comprehensive surveillance strategy alerts us to any unforeseen adverse reactions to the vaccine, to enable us to act swiftly when required.
In April 2021, we quickly responded to reports of extremely rare cases of concurrent thrombosis and thrombocytopenia following vaccination with the first dose of AstraZeneca. At that point, the Joint Committee on Vaccination and Immunisation advised that adults under 30 without underlying health issues should be offered an alternative vaccine to the AstraZeneca if one was available. That was later extended in May 2021 to adults under 40 without underlying health issues. The MHRA, as my hon. Friend the Member for North West Leicestershire (Andrew Bridgen) said, has undertaken a thorough review of UK reports of thrombosis and thrombocytopenia. While the estimated incident rate has increased over time as awareness of the condition increases across the healthcare system, the number of cases remains extremely low, given that more than 49 million doses of AstraZeneca covid-19 vaccine have been administered.
A number of colleagues asked about myocarditis. There is no evidence that people are at an increased risk of cardiac arrest in the days and weeks following the vaccine. The risk of getting myocarditis or pericarditis after the vaccine remains very low. A large study of 4 million vaccinated people in Denmark, published in the British Medical Journal, found that there were no deaths or diagnoses of heart failure in people who were diagnosed with myocarditis or pericarditis after being vaccinated.
In the highest-risk group, those aged 18 to 29, until the end of September this year there were 29 cases for every million second Pfizer doses and 68 cases for every million second Moderna doses given in the UK. The risk is much lower after a booster dose, and in other age groups the risk is lower still. However, it is worth remembering that catching covid-19 can significantly increase the risk of cardiac arrest and death, and the risk of developing myocarditis. There are an estimated 1,500 cases of myocarditis per million patients with covid—far greater than the risk of myocarditis following vaccination.
Let me turn now to some of the questions that have been asked. My hon. Friend the Member for Carshalton and Wallington asked about the inquiry and how people would be able to contribute to it. It will listen to and consider carefully the experiences of bereaved families and others who have suffered loss as a result of the pandemic. It will not consider individual cases; instead, listening to such accounts will inform its understanding of the impact of the pandemic and the response, and any lessons to be learned. Individuals will be able to engage through the inquiry’s listening exercise and the details of that will be brought forward in due course.
My hon. Friend the Member for Christchurch (Sir Christopher Chope) asked about informed consent. Indeed, I think that he produced the leaflet that provides the information that allows people to understand that the JCVI has recommended the vaccine because on balance it is beneficial to people; it is more likely to be of benefit to them than harm. Equally, however, each individual will be provided with information about the vaccine, as they are with all medical treatments, so that they know the benefits they can expect and the risk of side effects, however small, as well as what they are. As I say, he produced an example in the debate of a leaflet containing such information. What is important is that people are aware of the benefits and risks and can make informed decisions. Vaccination is not compulsory, but we are aware that it is of great benefit to the population and to individuals at risk of covid.
Sir Christopher Chope
What happens if somebody suffers a 50% disability as a result of having the vaccine, through an adverse reaction, or an unusual event? What do the Government do to help that person? They do not provide any compensation, or any special help through the health service, or a clinic, so what do they do?
Dr Johnson
My hon. Friend is talking about the vaccine damage payment scheme, which has been running since 1979 and provides a payment of up to £120,000—a tax-free lump sum, a one-off payment—for people who have been severely damaged by vaccines, on the balance of probabilities, which is determined when people apply. That does not prejudice any claim that they may have in a legal sense and they can still pursue a civil claim should they wish to do so. It has been asked whether there should be a separate scheme for covid, but of course it is right that all vaccines are treated in a similar fashion.
My hon. Friend the Member for Devizes (Danny Kruger) asked a few questions. He asked about the terms of reference of the inquiry being a matter for the chair, which indeed they are. He also asked whether I would commit the chair of the MHRA to meet specific people, but that is not for me to decide; it is up to the chair. My hon. Friend’s other question was about children’s vaccines. He is aware of my thoughts on that: it is important when we vaccinate children that the vaccines are of benefit to the child themselves. I am aware that when the vaccine was approved that was the decision made by all four chief medical officers and it is very important that the Government listen to and take medical advice. Since then, some things have changed. Natural immunity is more widespread and school disruption is no longer an issue. I understand that very shortly, at its next meeting, the JCVI will consider whether children’s vaccines should continue to be recommended, on the basis of the current situation. I think it is right that medical research is reviewed regularly as it becomes available and is taken into account.
The position of the MHRA remains that for most people the benefits of the covid-19 vaccine continue to outweigh the risks. The surveillance strategy is working, as we have discussed. We are able to respond quickly to ensure safe administration of all covid vaccines. I reiterate that the public should be very confident that all tests are completed to the very highest standards and that vaccines are safe.
Despite the progress we have made, we must not become complacent.
Sir Christopher Chope
Would the Minister be willing to address the all-party parliamentary group on covid-19 vaccine damage in a private meeting, so that she can hear at first hand some of the concerns that members have?
Dr Johnson
I thank my hon. Friend for that question. He will be aware of events today and I will at least have to see whether I remain in post before I potentially commit somebody else to such an event.
As I was saying, despite the progress we have made, we must not become complacent. We cannot risk an increase in serious illness, hospitalisations and deaths from covid. The UKHSA estimates that vaccinations had averted up to 128,000 deaths and 262,000 hospitalisations by the end of September 2021, and many more since then.
We must do everything in our power to protect those who are most vulnerable to the virus and keep pressure off the NHS in a tough winter period. Viruses such as covid-19 spread much more easily in winter when we socialise indoors. To protect those most at risk and help to reduce pressure on the NHS, we are delivering an autumn booster dose to those who are most in need of an extra layer of protection. Even if someone has had all of their jabs so far, and perhaps had covid too, they might still need an autumn booster to strengthen their protection. I encourage everyone who is eligible to come forward for their covid booster and seasonal flu jab today. To encourage vaccination against covid and flu and boost uptake, the NHS is making every effort to make it as convenient as possible for individuals to take up the offer, including offering both covid and flu vaccines at the same time, where possible, to reduce the number of appointments needed. Our NHS staff and volunteers are pulling out all the stops to deliver the next phase of the covid vaccine programme at speed once again, with more than 3,000 sites up and down the country involved.
The NHS was the first healthcare system in the world to deliver a covid-19 vaccine outside clinical trials, and it is now the first to deliver the new, variant-busting vaccine. Bivalent vaccines target two different strains of covid-19. They will give us a broader immunity and therefore potentially improve protection against variants of the virus. Whatever vaccine people receive in the autumn booster programme, they can be assured that it remains effective in preventing severe disease against all current variants and any potential future variants.
As I draw to a close, I thank my hon. Friend the Member for Carshalton and Wallington for bringing this important debate to the House at such an important time. The Government have already commissioned a public inquiry into the pandemic, and covid vaccines will be reviewed as part of that inquiry. There are no plans for an inquiry solely on vaccine safety. We face a tough winter ahead, and collectively we must do everything we can to protect those who are most vulnerable and to reduce pressure on the NHS. I encourage everyone who is eligible to step forward for their covid and flu vaccines as soon as they are able.